Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ513,55140,10
KB782,57830,00
PKN101,3101,35-0,98
Msft150,26150,360,25
Nokia3,12253,124-0,51
IBM134,58135,220,60
Daimler AG50,150,11-1,14
PFE37,2737,440,38
18.11.2019 12:24:57
Indexy online
AD Index online
select
AD Index online
 

  • 15.11.2019
Thermo Fisher Scientific (TMO, NY Consolidated)
Závěr k 15.11.2019 Změna (%) Změna (USD) Objem obchodů (ks)
306,81 1,98 5,97 1 626 984
Premarket18.11.2019 10:33:04
Poslední obchod Nákup / Prodej Změna (%) Změna (USD) Objem obchodů (ks)
- 308,20 330,00 - - -
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 18.11.2019
Popis společnosti
Obecné informace
Název společnostiThermo Fisher Scientific Inc.
TickerTMO
Kmenové akcie:Ordinary Shares
RICTMO
ISINUS8835561023
Poslední známé roční výsledky31.12.2018
Poslední známé čtvrtletní výsledky28.09.2019
Počet zaměstnanců k 31.12.2018 70 000
Akcie v oběhu k 28.09.2019 400 991 227
Počet akcionářů k 31.12.2018 3 344
MěnaUSD
Konstituent indexůS&P 500
Kontaktní informace
Ulice168 3rd Ave
MěstoWALTHAM
PSČ02451-7551
ZeměUnited States
Kontatní osobaKenneth Apicerno
Funkce kontaktní osobyVice President, Investor Relations
Telefon17 816 221 000
Fax17816221207
Kontatní telefon17 816 221 294

Business Summary: Thermo Fisher Scientific Inc. develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services. The Life Sciences Solutions segment provides a portfolio of reagents, instruments and consumables. The Analytical Instruments segment provides a range of instruments, consumables, software and services. The Specialty Diagnostics segment offers a range of diagnostic test kits, reagents, culture media, instruments and associated products. The Laboratory Products and Services segment offers controlled temperature technologies products, growth protection and separation products, and water and laboratory products.
Financial Summary: BRIEF: For the nine months ended 28 September 2019, Thermo Fisher Scientific Inc. revenues increased 5% to $18.71B. Net income before extraordinary items increased 23% to $2.66B. Revenues reflect Life Sciences Solutions segment increase of 10% to $5.02B, Laboratory products and services segment increase of 4% to $7.77B, Analytical Technologies segment increase of 3% to $4B.
Odvětvová klasifikace
TRBC2009Advanced Medical Equipment
TRBC2012Advanced Medical Equipment & Technology - NEC
RBSS2004Advanced Medical Equipment
MGINDUSTRYMedical Equipment & Supplies
MGSECTORHealthcare
NAICSElectromedical and Electrotherapeutic Apparatus Manufacturing
NAICSTesting Laboratories
NAICSResearch and Development in the Physical, Engineering, and Life Sciences
NAICSSoftware Publishers
NAICSFlat Glass Manufacturing
NAICSOther Measuring and Controlling Device Manufacturing
NAICSInstruments and Related Products Manufacturing for Measuring, Displaying, and Controlling Industrial Process Variables
NAICSInVitro Diagnostic Substance Manufacturing
NAICSSurgical Appliance and Supplies Manufacturing
NAICSAnalytical Laboratory Instrument Manufacturing
SICMeasuring/controlling Devices Nec
SICElectromedical Equipment
SICTesting Laboratories
SICCommercial Physical Research
SICPrepackaged Software
SICFlat Glass
SICMeasuring/controlling Devices Nec
SICProcess Control Instruments
SICDiagnostic Substances
SICSurgical Appliances And Supplies
SICAnalytical Instruments



  • Poslední aktualizace: 18.11.2019
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Independent Chairman of the BoardJim Manzi6711.05.200711.05.2007
President, Chief Executive Officer, DirectorMarc Casper5115.10.2009
Chief Financial Officer, Senior Vice PresidentStephen Williamson5201.08.201501.08.2015
Chief Operating Officer, Executive Vice PresidentMark Stevenson5601.08.2017
Senior Vice President, General CounselMichael Boxer57
Senior Vice PresidentGregory Herrema5315.05.2008
Senior Vice President and President, Pharma ServicesMichel Lagarde44
Vice President, Chief Accounting OfficerPeter Hornstra59